Issue 43, 2021

Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

Abstract

Once the World Health Organization (WHO) declared the COVID-19 outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Here we review the most recent data on the novel SARS-CoV-2 pathogen. We analyzed its etiology, pathogenesis, diagnosis, prevention, and current medications. After that, we summarized the promising drug delivery application of nanomaterial-based systems. Their preparation routes, unique advantages over the traditional drug delivery routes and their toxicity though risk analysis were also covered. We also discussed in detail the mechanism of action for one example of drug-loaded nanomaterial drug delivery systems (Avigan-contained nano-emulsions). This review provides insights about employing nanomaterial-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reducing their toxicity, and to increase their efficiency.

Graphical abstract: Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

Article information

Article type
Review Article
Submitted
22 6 2021
Accepted
27 7 2021
First published
02 8 2021
This article is Open Access
Creative Commons BY license

RSC Adv., 2021,11, 26463-26480

Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19

M. Abd Elkodous, S. O. Olojede, M. Morsi and G. S. El-Sayyad, RSC Adv., 2021, 11, 26463 DOI: 10.1039/D1RA04835J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements